Limiting peak plasma concentration effectively decreases remifentanil-induced coughing during target-controlled infusion.
J-Y
JY
Kim
F-S
FS
Nahm
Y-O
YO
Park
D000328:Adult; D000368:Aged; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D003371:Cough / Q000139:chemically induced*; D004311:Double-Blind Method; D016503:Drug Delivery Systems / Q000379:methods*; D017558:Elective Surgical Procedures; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D011446:Prospective Studies; D000077208:Remifentanil; D012720:Severity of Illness Index; D013997:Time Factors
D018686:Anesthetics, Intravenous; D010880:Piperidines; D000077208:Remifentanil